Denali Therapeutics upsizes IPO, to raise $250 million at midpoint of price range
Biotech Denali Therapeutics Inc. increased the size of its planned initial public offering Thursday, saying it now intends to say 13.9 million shares priced at $17 to $19 a pop. The company would raise $250 million at the midpoint of that range, up from a previous plan to raise $150 million. The company is planning to list on Nasdaq under the ticker symbol "DNLI". Goldman Sachs, Morgan Stanley and J.P. Morgan are underwriters on the deal with Evercore ISI acting as co-manager.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.